News | April 25, 2026
Bayer’s comeback gains speed as CEO warns: “The Work Isn’t Complete. Yet"
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
The collaboration will roll out an “agentic” AI platform across Merck’s research & development, manufacturing, commercial, and corporate operations
Growth was broad-based across segments
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
Subscribe To Our Newsletter & Stay Updated
